A61P 19 - Drugs for skeletal disorders

Patents for A61P 19 - Drugs for skeletal disorders (81,981)
12/2002
12/18/2002	EP1265839A1 Compounds active at the glucocorticoid receptor
12/18/2002	EP1265637A2 Compositions and methods for affecting osteogenesis
12/18/2002	EP1265630A2 Use of insulin for the treatment of cartilagenous disorders
12/18/2002	EP1265616A2 Hormone replacement therapy using a combination of conjugated estrogens and medroxyprogesterone acetate
12/18/2002	EP1265606A1 Cell adhesion inhibitors
12/18/2002	EP1265603A2 Il-8 receptor antagonists
12/18/2002	EP1124814B1 Aromatic derivatives and iron complexes thereof for the use as normalising agents of the iron level
12/18/2002	EP1104420B1 Substituted 1,8-naphthyridin-4(1h)-ones as phosphodiesterase 4 inhibitors
12/18/2002	EP0946502B1 Sulfonamide interleukin-beta converting enzyme inhibitors
12/18/2002	EP0934300B1 The preparation and use of ortho-sulfonamido heteroaryl hydroxamic acids as matrix metalloproteinase and tace inhibitors
12/18/2002	EP0859784B1 Thio-substituted peptides as inhibitors for metalloproteinases and tnf liberation
12/18/2002	CN1385209A Gukang powder medicine for treating bone disease
12/18/2002	CN1385186A Traditional Chinese medicine for treating arthralgia-syndrome due to wind-cold-dampress and formula and preparation process thereof
12/18/2002	CN1385182A External medicine composition for curing arthralgia-syndrome of joint and preparation process thereof
12/18/2002	CN1385181A Capsule for strengthening bones and muscles and preparation method thereof
12/18/2002	CN1385175A Medicine for treating dermatomyositis
12/18/2002	CN1096276C External-use antalgic liquid for early stage of bone fracture and injury
12/18/2002	CA2388761A1 Wound healing biomarkers
12/17/2002	US6495736 Compositions and methods for increasing bone mineralization
12/17/2002	US6495687 Adenosine receptors are involved in a vast number of peripheral and central regulatory mechanisms such as, for example, vasodilation, cardiac depression, inhibition of lipolysis, inhibition of insulin release and potentiation
12/17/2002	US6495662 Bioactive peptides and peptide derivatives of parathyroid hormone (PTH) and parathyroid hormone-related peptide (PTHrP)
12/17/2002	US6495607 Benzocycloheptenes, process for their production, pharmaceutical preparations that contain the latter as well as their use for the production of pharmaceutical agents
12/17/2002	US6495606 Administering s-((r)-2-(1-iminoethylamino)propyl)-l-cysteine
12/17/2002	US6495582 Erk (extracellular signal regulated kinase) inhibitors for treatment of cancer, inflammatory disorders, restenosis, and cardiovascular disease
12/17/2002	US6495578 Sulfonamide derivatives having oxadiazole rings
12/17/2002	US6495568 Treatment of tissue ulceration, wound repair and skin diseases
12/17/2002	US6495565 For therapy of acute infection, acute phase response, age related macular degeneration, alcoholism, anorexia, asthma, autoimmune disease, autoimmune hepatitis, bechet's disease, cachexia, calcium pyrophosphate dihydrtate deposition
12/17/2002	US6495564 Such as 3-(6-((4-chloro-phenyl)-hydroxy-(3-methyl-3h-imidazol-4-yl)-methyl)-1-methyl-2-oxo-1,2-dihydro-quinolin-4-yl)-benzaldehyde o-methyl-oxime; inhibiting abnormal cell growth
12/17/2002	US6495560 10,11-dihydro-3-(2-(5,6,7,8-tetrahydro-1,8-naphthyridin-2-yl)-1 -ethoxy)-5h-dibenzo(a,d)cycloheptene-10-acetic acid; treatment of osteoporosis
12/17/2002	US6495559 For therapy of obesity
12/17/2002	US6495545 1,4-benzodiazepinone derivatives and their use as integrin antagonists
12/17/2002	US6495544 Homoiminopiperidinyl hexanoic acid inhibitors of inducible nitric oxide synthase
12/17/2002	US6495519 Interleukin-1 β converting enzyme like apoptosis protease-3 and 4
12/17/2002	US6495516 Method for killing gram-negative bacteria with biologically active peptides from functional domains of bacterial/permeability-increasing protein
12/17/2002	US6495128 Human chemokine β-7 deletion and substitution proteins
12/17/2002	CA2131822C Use of estriol for treating climacteric osteoporosis
12/14/2002	CA2390686A1 Cofactor-based screening method for nuclear receptor modulators and related modulators
12/12/2002	WO2002099388A2 Benzodiazepine bradykinin antagonists
12/12/2002	WO2002099115A2 Nucleic acid-associated proteins
12/12/2002	WO2002099037A2 Compositions and methods for systemic administration of sequences encoding bone morphogenetic proteins
12/12/2002	WO2002098880A1 5-ethyl-imidazotriazinones
12/12/2002	WO2002098877A1 Pyrazino 1',2':1,6 pyrido 3,4-b indole1,4-dione derivatives
12/12/2002	WO2002098875A1 Carboline derivatives as pde-5 inhibitors
12/12/2002	WO2002098873A1 2-heteroaryl-imidazotriazinones and their use in the treatment of inflammatory or immune diseases
12/12/2002	WO2002098869A2 1,4-disubstituted benzo-fused cycloalkyl urea compounds
12/12/2002	WO2002098868A1 Epothilone derivatives
12/12/2002	WO2002098850A2 Chemical compounds and pharmaceutical compositions as cathepsin s inhibitors
12/12/2002	WO2002098840A1 Carboxylic acid derivative and medicine comprising salt or ester of the same
12/12/2002	WO2002098453A2 Orally administering parathyroid hormone and calcitonin
12/12/2002	WO2002098451A1 Mixtures of calcitonin drug-oligomer conjugates comprising polyalkylene glycol, uses thereof, and methods of making same
12/12/2002	WO2002098449A1 Remedies for joint injury and functional foods
12/12/2002	WO2002098438A1 Compositions containing an active fraction isolated from scutellariae barbatae and methods of use
12/12/2002	WO2002098434A1 Method of producing calcium gluconolactate, compositions, processes and uses of same
12/12/2002	WO2002098428A1 Tetracyclic compounds as pde5-inhibitors
12/12/2002	WO2002098426A1 Substituted tetrahydroisoquinolines for use in the treatment of inflammatory diseases
12/12/2002	WO2002098406A1 Novel compounds and compositions as cathepsin inhibitors
12/12/2002	WO2002098391A2 Process for preparing granular compositions
12/12/2002	WO2002098362A2 Use of rank antagonists to treat cancer
12/12/2002	WO2002098354A2 Compositions and methods for inhibiting bone resorption
12/12/2002	WO2002098352A2 PHARMACEUTICAL COMPOSITIONS FOR THE COORDINATED DELIVERY OF NSAIDs
12/12/2002	WO2002098346A2 Method and pharmaceutical composition for the treatment of multiple sclerosis
12/12/2002	WO2002098307A1 A device for the delivery of a drug to a fractured bone
12/12/2002	WO2002083879A3 Immunotherapy based on dendritic cells
12/12/2002	WO2002076977A3 Rho-kinase inhibitors
12/12/2002	WO2002076976A3 Rho-kinase inhibitors
12/12/2002	WO2002076508B1 Methods for delivering nucleic acid molecules into cells and assessment thereof
12/12/2002	WO2002072548A3 Heterocyclic compounds and their use as histamine h4 ligands.
12/12/2002	WO2002066458A3 2-thio-substituted imidazole derivatives and the use thereof in the pharmaceutical industry
12/12/2002	WO2002064591A3 Carboline derivatives
12/12/2002	WO2002064552A8 1g(a)-AMINO-N-HYDROXY-ACETAMIDE DERIVATIVES
12/12/2002	WO2002064543A3 Novel succinate salt of o-desmethyl-venlafaxine
12/12/2002	WO2002064080A3 Matrix metalloproteinase inhibitors
12/12/2002	WO2002061052A3 An improved in vitro method of culturing mammalian cells for autologous cell implantation/transplantation methods
12/12/2002	WO2002059612A3 Animal model and cell-line expressing modified chlorine channel
12/12/2002	WO2002029044A3 Modulation of the transcription of pro-inflammatory gene products
12/12/2002	WO2001097850A3 Combinations and compositions which interfere with vegf/vegf and angiopoietin/tie receptor function and their use (ii)
12/12/2002	WO2001093983A9 Secreted and transmembrane polypeptides and nucleic acids encoding the same
12/12/2002	US20020188134 Pharmaceutical compositions
12/12/2002	US20020188122 Such as pyridine-4-carboxaldehyde-(4-Morpholinylprop-3-yl) imine for use in therapy as cytokine inhibitors
12/12/2002	US20020188118 Compounds and methods for the inhibition of the expression of VCAM-1
12/12/2002	US20020188015 Method and composition for rejuvinating cells, tissues organs, hair and nails
12/12/2002	US20020187991 Barbituric acid derivatives
12/12/2002	US20020187978 4-Heteroaryl-3-heteroarylidenyl-2-indolinones and their use as protein kinase inhibitors
12/12/2002	US20020187976 New benzofurane derivatives, their preparation process, their use as medicaments and the pharmaceutical compositions containing them
12/12/2002	US20020187973 Pharmaceutical compositions and uses for androst-5-ene-3beta, 17beta-diol
12/12/2002	US20020187970 Pharmaceutical compositions and uses for androst-5-ene-3beta, 17beta-DIOL
12/12/2002	US20020187969 Pharmaceutical compositions and uses for androst-5-ene-3beta, 17beta-diol
12/12/2002	US20020187968 Pharmaceutical compositions and uses for androst-5-ene-3beta, 17beta-DIOL
12/12/2002	US20020187967 Pharmaceutical compositions and uses for androst-5-ene-3beta, 17beta-diol
12/12/2002	US20020187966 Pharmaceutical compositions and uses for androst-5-ene-3beta, 17beta-diol
12/12/2002	US20020187965 Pharmaceutical compositions and uses for androst-5-ene-3beta, 17beta-diol
12/12/2002	US20020187964 Pharmaceutical compositions and uses for androst-5-ene-3beta, 17beta-diol
12/12/2002	US20020187963 Pharmaceutical compositions and uses for androst-5-ene-3beta, 17beta-diol
12/12/2002	US20020187962 Pharmaceutical compositions and uses for androst-5-ene-3beta, 17beta-diol
12/12/2002	US20020187953 Estrogen receptor-related receptor alpha (ERRalpha) and cartilage formation
12/12/2002	US20020187947 Inflammation-related gene
12/12/2002	US20020187492 Nucleotide sequences coding polypeptides for use in the treatnment of inflammation
12/12/2002	US20020187186 Pharmaceutical tablets
12/12/2002	CA2449686A1 Mixtures of calcitonin drug-oligomer conjugates comprising polyalkylene glycol, uses thereof, and methods of making same
12/12/2002	CA2449658A1 Use of rank antagonists to treat cancer

1 ... 616 617 618 619 620 621 622 623 624 625 626 627 628 629 630 631 632 633 634 635 636 ... 820